Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Robert C. Doebele; David Spigel; Mustapha Tehfe; Sachdev Thomas; Martin Reck; Sunil Verma; Janice Eakle; Frederique Bustin; Jerome Goldschmidt; Dachuang Cao; Ekaterine Alexandris; Sergey Yurasov; D. Ross Camidge; Philip Bonomi

doi:10.1002/cncr.29132

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer

Cancer ◽

10.1002/cncr.29132 ◽

2014 ◽

Vol 121 (6) ◽

pp. 883-892 ◽

Cited By ~ 30

Author(s):

Robert C. Doebele ◽

David Spigel ◽

Mustapha Tehfe ◽

Sachdev Thomas ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Chemotherapy

Download Full-text

A phase 2 randomized open-label study of ramucirumab (RAM) plus first-line platinum-based chemotherapy in patients (pts) with recurrent or advanced non-small cell lung cancer (NSCLC): Final results from squamous pts

Annals of Oncology ◽

10.1093/annonc/mdx091.039 ◽

2017 ◽

Vol 28 ◽

pp. ii42-ii43

Author(s):

S. Thomas ◽

R.C. Doebele ◽

D. Spigel ◽

M. Tehfe ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Download Full-text

A Phase 2 Randomized Open-Label Study of Ramucirumab (IMC 1121b; RAM) in Combination with Platinum-Based Chemotherapy in Patients (PTS) with Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Results From Non-Squamous (NSQ) PTS (NCT01160744)

Annals of Oncology ◽

10.1016/s0923-7534(20)33839-4 ◽

2012 ◽

Vol 23 ◽

pp. ix408 ◽

Cited By ~ 1

Author(s):

R. Doebele ◽

D. Spigel ◽

M. Tehfe ◽

S. Thomas ◽

M. Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Download Full-text

A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000273 ◽

2014 ◽

Vol 9 (10) ◽

pp. 1532-1539 ◽

Cited By ~ 23

Author(s):

D. Ross Camidge ◽

Eamon M. Berge ◽

Robert C. Doebele ◽

Marc S. Ballas ◽

Thierry Jahan ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy

Download Full-text

65Plus: open-label study of bevacizumab in combination with pemetrexed or pemetrexed/carboplatin as first-line treatment of patients with advanced or recurrent nonsquamous non-small-cell lung cancer

Lung Cancer Targets and Therapy ◽

10.2147/lctt.s142972 ◽

2017 ◽

Vol Volume 8 ◽

pp. 217-229

Author(s):

Wolfgang Schuette ◽

Claus-Peter Schneider ◽

Walburga Engel-Riedel ◽

Christian Schumann ◽

Martin Kohlhaeufl ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Small Cell ◽

Line Treatment ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Treatment

Download Full-text

MO01.29 Randomized, Open-Label Study of Bintrafusp Alfa vs. Pembrolizumab as First-Line (1L) Treatment in Patients with PD-L1–Expressing Advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.10.134 ◽

2021 ◽

Vol 16 (1) ◽

pp. S27-S28

Author(s):

M.-J. Ahn ◽

F. Barlesi ◽

E. Felip ◽

E. Garon ◽

C.M. Martin ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Final Results of a Phase 2, Open-Label Study of Ramucirumab (IMC-1121B; RAM), an IGG1 MAB Targeting Vegfr-2, with Paclitaxel and Carboplatin as First-Line Therapy in Patients (PTS) with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) (NCT00735696)

Annals of Oncology ◽

10.1016/s0923-7534(20)33884-9 ◽

2012 ◽

Vol 23 ◽

pp. ix422-ix423

Author(s):

D.R. Camidge ◽

R.C. Doebele ◽

M. Ballas ◽

T. Jahan ◽

M. Haigentz ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase 2 ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

First Line Therapy ◽

Line Therapy

Download Full-text

Erratum to: Final overall survival in JO22903, a phase II, open-label study of first-line erlotinib for Japanese patients with EGFR mutation-positive non-small-cell lung cancer

International Journal of Clinical Oncology ◽

10.1007/s10147-016-1052-3 ◽

2016 ◽

Vol 22 (1) ◽

pp. 79-79 ◽

Cited By ~ 1

Author(s):

Noboru Yamamoto ◽

Koichi Goto ◽

Makoto Nishio ◽

Kenichi Chikamori ◽

Toyoaki Hida ◽

...

Keyword(s):

Lung Cancer ◽

Overall Survival ◽

Egfr Mutation ◽

Japanese Patients ◽

Small Cell ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

Second-line erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): Results from a large, open-label study

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.19002 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 19002-19002

Author(s):

L. Crinò ◽

M. Boyer ◽

W. E. Eberhardt ◽

Z. Balikó ◽

E. F. Smit

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Second Line ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study

Download Full-text

A randomized open-label study of gefitinib versus docetaxel in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who have previously received platinum-based chemotherapy

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8025 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8025-8025 ◽

Cited By ~ 8

Author(s):

D. Lee ◽

S. Kim ◽

K. Park ◽

J. Kim ◽

J. Lee ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Small Cell ◽

Small Cell Lung ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Platinum Based Chemotherapy

Download Full-text

168TiP KEYNOTE-A86: Phase III, randomized, open-label study of first-line subcutaneous (SC) vs intravenous (IV) pembrolizumab with platinum doublet chemotherapy in metastatic squamous or nonsquamous non-small cell lung cancer (NSCLC)

Annals of Oncology ◽

10.1016/j.annonc.2021.10.187 ◽

2021 ◽

Vol 32 ◽

pp. S1456

Author(s):

B. Halmos ◽

P. Cobb ◽

M.L. Johnson ◽

L. Jain ◽

S.J. Kim ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell ◽

Phase Iii ◽

Small Cell Lung ◽

First Line ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Doublet Chemotherapy ◽

Platinum Doublet

Download Full-text